Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
A Phase I Study of Oral Decitabine and Cedazuridine (ASTX727) In Combination With Defactinib (VS-6063) as Therapy of Myelodysplastic Syndromes and Low-blast Acute Myeloid Leukaemia
Sponsor: Australian National University
This PHASE1 trial investigates Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia and is currently actively recruiting participants. Australian National University leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1
-
Feb 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Feb 2023 — Jan 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Dec 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Australian National University
- Clinical Hub for Interventional Research (CHOIR)
- The University of New South Wales
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Sydney, Australia
- • Westmead, Australia